This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Bristol-Myers Squibb.
Reference
Freeman M, et al. Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data. Advances in Therapy : 22 Aug 2019. Available from: URL: http://doi.org/10.1007/s12325-019-01060-y
Rights and permissions
About this article
Cite this article
Nivolumab in resected melanoma: clinical benefits at lower cost. PharmacoEcon Outcomes News 836, 18 (2019). https://doi.org/10.1007/s40274-019-6191-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6191-0